Short manuscripts of 5 pages maximum (4 for text and 1 for acknowledgment and references). Communications may be peer reviewed through the normal process; or they may follow an expedited review process at the Editor-in-Chief’s discretion. Ideal Communications are accompanied by additional material such as video, databases, and executable codes of any models as provided by the authors. Communications should report on new results on novel technologies in early translational development phase, early clinical implementation and validation, or discussion of emerging challenges and unmet needs.
Download the Communication Template
Structured Abstract: Limited to 150 words with the following headings (headings do not contribute to the word count):
Index Terms: Up to 5 keywords in alphabetical order.
Clinical and Translational Impact Statement: An impact statement of no more than 30 words. The statement should address how the reported findings serve to improve human health (or provide a path to improving health), and articulate a strategy for how the reported device, diagnostic, therapeutic, or service may be integrated into a clinical or home healthcare setting. The authors are encouraged to review the NIH Clinical Spectrum (see below) and indicate the best category for the reported work: Early/Pre-Clinical Research, Clinical Research, Clinical Implementation, or Public Health. Any submission without this statement will be returned to the author without review.
Body: The main manuscript body organized in the following manner:
- Introduction and Clinical Need
- Future Directions and Potential Clinical Impact
- Acknowledgment (not required, but encouraged)
- Appendix/Supplemental Material (if desired)